Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genkyotex    GKTX   FR0011790542

GENKYOTEX (GKTX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:07 pm
1.05 EUR   +16.28%
09/21GENKYOTEX SA : half-yearly earnings release
2017GENKYOTEX SA : half-yearly earnings release
2017GENKYOTEX SA : annual earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
0.942(c) 0.92(c) 0.912(c) 0.903(c) 1.05(c) Last
145 380 242 017 422 322 119 789 396 609 Volume
-8.01% -2.34% -0.87% -0.99% +16.28% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -13,3 M
Net income 2018 -12,3 M
Finance 2018 10,0 M
Yield 2018 -
Sales 2019 50,0 M
EBIT 2019 23,5 M
Net income 2019 15,7 M
Debt 2019 18,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 4,37
EV / Sales2018 0
EV / Sales2019 1,78x
Capitalization 71,1 M
More Financials
Company
Genkyotex specializes in the development of NOX therapies. The group adopts a therapeutic approach based on the selective inhibition of NOX enzymes that boost numbers of pathological processes including fibrosis, inflammation, pain sensation, cancer progression and neurodegeneration. At the end... 
More about the company
Surperformance© ratings of Genkyotex
Trading Rating : Investor Rating : -
More Ratings
Latest news on GENKYOTEX
10/16GENKYOTEX : Announces Presentation of GKT831 Efficacy Data in a Preclinical Mode..
AQ
09/27GENKYOTEX : Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 f..
AQ
09/21GENKYOTEX SA : half-yearly earnings release
08/02GENKYOTEX : Announces Investigator-Initiated Phase 2 Clinical Trial to be Conduc..
AQ
07/12GENKYOTEX : Half-yearly report on Genkyotex's liquidity contract
PU
05/08GENKYOTEX : Announces Positive Outcome from Independent SMBs First Pre-Planned R..
AQ
2017GENKYOTEX SA : half-yearly earnings release
2017GENKYOTEX : Summary of Genkyotex's liquidity contract with ODDO Corporate Financ..
PU
2017GENTICEL BECOMES “GENKYOTEX&RD : Genticel's General Meeting approves the s..
PU
2017GENKYOTEX SA : annual earnings release
More news
Analyst Recommendations on GENKYOTEX
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart GENKYOTEX
Duration : Period :
Genkyotex Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENKYOTEX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,90 €
Spread / Average Target 332%
EPS Revisions
Managers
NameTitle
Elias Papatheodorou Chief Executive Officer & Director
Claudio Nessi Chairman
Alexandre Grassin Vice President-Finance & Administration
Philippe Wiesel Chief Medical Officer & Executive Vice President
Jesús Martin-Garcia Director
Sector and Competitors
1st jan.Capitalization (M$)
GENKYOTEX-45.60%81
GILEAD SCIENCES-5.99%87 125
VERTEX PHARMACEUTICALS17.08%44 319
REGENERON PHARMACEUTICALS0.68%40 244
GENMAB3.74%9 984
SAREPTA THERAPEUTICS INC119.30%8 154